Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 482 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inflammatory Tissue Disorder Clear all
Completed No phase listed Observational

Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass

NCT01433302
View directory record Official record
Conditions
Breast Cancer, Genitourinary Cancer, Malignant Female Reproductive System Neoplasm, Melanoma, Sarcoma
Interventions
Punch Biopsy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 23, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

NCT03104374
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
72
States / cities
Mobile, Alabama • Mesa, Arizona • Peoria, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 23, 2026, 8:45 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

NCT05322473
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Sonelokimab (M1095), Adalimumab, Placebo
Drug · Other
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
Fountain Valley, California • Los Angeles, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 8:45 PM EDT
Withdrawn No phase listed Observational

Effects of Bariatric Surgery on Breast Density Improvement and Impact on Breast Cancer Risk in Severe Obese Patients

NCT04170335
View directory record Official record
Conditions
Breast Cancer, Morbid Obesity, Bariatric Surgery Candidate
Interventions
Bariatric surgery
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 74 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 23, 2026, 8:45 PM EDT
Completed No phase listed Observational

Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis

NCT00646555
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 8:45 PM EDT
Completed Not applicable Interventional Results available

Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis

NCT04271735
View directory record Official record
Conditions
Psoriasis, Atherosclerotic Cardiovascular Disease, Obesity, Dyslipidemia, Cardiometabolic Diseases
Interventions
Niagen, Placebo
Dietary Supplement · Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 8:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease

NCT00069329
View directory record Official record
Conditions
Nervous System Malformations, Arthropathy, Neurogenic, Urticaria, Papilledema
Interventions
anakinra
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 23, 2026, 8:45 PM EDT
Completed Phase 2 Interventional Results available

Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer

NCT01417286
View directory record Official record
Conditions
Inflammatory Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Tubular Ductal Breast Carcinoma
Interventions
External beam radiation therapy
Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
2
States / cities
New Brunswick, New Jersey • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 23, 2026, 8:45 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT04306939
View directory record Official record
Conditions
Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions
venipuncture, Questionnaires, Additional Sample Collections
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 23, 2026, 8:45 PM EDT
Completed Phase 2 Interventional Results available

Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks

NCT00147498
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
24
States / cities
Upland, California • Clearwater, Florida • Miami, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 23, 2026, 8:45 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability

NCT03962998
View directory record Official record
Conditions
Crohn Disease
Interventions
Lactulose/Rhamnose solution, MB-102
Drug
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 23, 2026, 8:45 PM EDT
Recruiting No phase listed Observational

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

NCT01802034
View directory record Official record
Conditions
Kidney Diseases, Kidney Failure, Chronic, Diabetic Nephropathy, Lupus Nephritis, Glomerulonephritis, IGA
Interventions
Not listed
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 23, 2026, 8:45 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

NCT00295893
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, docetaxel, doxorubicin hydrochloride, Trastuzumab, Carboplatin, Paclitaxel
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 8:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers

NCT02045264
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
Icatibant (30 mg)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 23, 2026, 8:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers

NCT00001164
View directory record Official record
Conditions
Healthy, Muscular Dystrophy, Retinal Degeneration, Skin Diseases, Virus Diseases
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
1978 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Oct 23, 2026, 8:45 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease

NCT00511329
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid, Crohn Disease
Interventions
somatropin [rDNA origin] for injection
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Oct 23, 2026, 8:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

NCT06239272
View directory record Official record
Conditions
Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma, Fibrosarcoma NOS, Myxofibrosarcoma, Angiosarcoma, Osteosarcoma, Extraskeletal, Dedifferentiated Liposarcoma, Myxoid Liposarcoma, Pleomorphic Liposarcoma, Myxoid Pleomorphic Liposarcoma, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, Malignant Tenosynovial Giant Cell Tumor of Soft Tissue, Epithelioid Hemangioendothelioma, Glomus Tumor, Inflammatory Leiomyosarcoma, Leiomyosarcoma, Ossifying Fibromyxoid Tumor, Malignant, Myoepithelioma, Synovial Sarcoma, Epithelioid Sarcoma, Perineurioma, Malignant, Clear Cell Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Granular Cell Tumor, Malignant, Melanotic Malignant Nerve Sheath Tumor, Malignant Peripheral Nerve Sheath Tumor, Perivascular Epithelioid Tumor, Malignant, Intimal Sarcoma, Myoepithelial Carcinoma, Undifferentiated Sarcoma, Pleomorphic Sarcoma, Undifferentiated, Round Cell Sarcoma, Undifferentiated, NTRK-Rearranged Spindle Cell Neoplasm, Phosphaturic Mesenchymal Tumor, Malignant, Round Cell Sarcoma, Well Differentiated Liposarcoma, Giant Cell Tumor of Soft Parts NOS, Low Grade Myofibroblastic Sarcoma, Dermatofibrosarcoma Protuberans, Fibrosarcomatous
Interventions
Surgical resection, Proton beam radiation therapy, Pazopanib, Ifosfamide, Doxorubicin, Selinexor
Procedure · Radiation · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 30 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Baton Rouge, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 23, 2026, 8:45 PM EDT
Completed Not applicable Interventional

Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease

NCT01656746
View directory record Official record
Conditions
Adenomatous Polyp, Crohn Disease, Familial Adenomatous Polyposis, Hereditary Intestinal Polyposis Syndrome, Recurrent Colon Cancer, Stage I Colon Cancer, Stage IIA Colon Cancer, Stage IIB Colon Cancer, Stage IIC Colon Cancer, Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer
Interventions
therapeutic laparoscopic surgery
Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 23, 2026, 8:45 PM EDT
Completed Phase 2 Interventional Results available

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

NCT01796197
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab, Pertuzumab, Paclitaxel, Doxorubicin, Cyclophosphamide, Mastectomy, Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 23, 2026, 8:45 PM EDT
Completed Phase 2 Interventional

Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies

NCT00001261
View directory record Official record
Conditions
Dermatomyositis, Inclusion Body Myositis, Polymyositis
Interventions
Gamma Globulin
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 8:45 PM EDT
Completed No phase listed Observational

Evaluation and Treatment of Patients With Inflammatory Eye Diseases

NCT00006188
View directory record Official record
Conditions
Choroiditis, Iridocyclitis, Iritis, Retinal Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
4 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 8:45 PM EDT
Not listed Phase 1 Interventional

Dose-escalation Study of Oral CX-4945

NCT00891280
View directory record Official record
Conditions
Advanced Solid Tumors, Breast Cancer, Inflammatory Breast Cancer, Castleman's Disease, Multiple Myeloma
Interventions
CX-4945 oral formulation
Drug
Lead sponsor
Cylene Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Scottsdale, Arizona • Fort Collins, Colorado • Loveland, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2011 · Synced Oct 23, 2026, 8:45 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 23, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

NCT00685373
View directory record Official record
Conditions
Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
Interventions
Canakinumab (ACZ885)
Drug
Lead sponsor
Novartis
Industry
Eligibility
3 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 23, 2026, 8:45 PM EDT